Affiliation:
1. Lepetit Research Center, Marion Merrell Dow Research Institute, Gerenzano, Varese, Italy.
Abstract
MDL 62,879 (GE2270 A) is a new peptide antibiotic that inhibits protein synthesis through an interaction with elongation factor Tu. MDL 62,879 was very active against gram-positive clinical isolates, particularly staphylococci and enterococci, for which MICs for 90% of isolates were < or = 0.13 micrograms/ml. It was equally active against isolates resistant to beta-lactams, erythromycin, gentamicin, and glycopeptides. It also had activity against Mycobacterium tuberculosis. MDL 62,879 had moderate bactericidal activity against staphylococci.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference16 articles.
1. New antibiotic that acts specifically on the GTP-bound form of elongation factor Tu;Anborgh P. H.;EMBO J.,1991
2. Efrotomycin, a drug for swine dysentery control;Foster A. G.;J. Anim. Sci.,1976
3. Goldstein B. P. M. Berti F. Ripamonti G. P. Candiani G. Romano S. Bellini and M. Denaro. 1990. Program Abstr. 30th Intersci. Conf. Antimicrob. Agents Chemother. abstr. 800.
4. Methicillin-resistant Staphylococcus aureus-a reappraisal;Keane C. T.;J. Hosp. Infect.,1991
5. In vitro activity of MDL 62,879 (GE2270) against aerobic gram-positive and anaerobic bacteria;King A.;Antimicrob. Agents Chemother.,1993
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献